MJMonica J. Janke

Monica J. Janke

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Monica J. Janke has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Epidural Analgesia for Gynecologic Oncology Patients Undergoing Laparotomy: A Retrospective Analysis and Systematic Review of Perioperative Outcomes

    by Annie Minns, Alli M. Straubhar, Monica J. Janke, Yang Liu, LaTeesa James, Cynthia Stroup, Shitanshu Uppal, Zhen Ni Zhou

    To investigate the impact of perioperative epidurals on postoperative pain, hospital length of stay (LOS), opioid use, and perioperative complications in gynecologic oncology patients undergoing laparotomy. We conducted a retrospective cohort study of patients undergoing laparotomy for a suspected or known gynecologic malignancy at a single tertiary cancer center using an enhanced recovery after surgery protocol without routine epidural analgesia use. Patients received either (1) epidural analgesia or (2) no regional analgesia. Propensity score matching was performed to adjust for confounding factors. Additionally, we conducted a systematic review and qualitative analysis. The primary outcome was postoperative pain. Secondary outcomes included LOS, opioid use, and postoperative complications. Of 530 patients meeting inclusion criteria, 20 (3.7%) received epidurals, and 510 (96.2%) did not. After propensity score matching, no differences in pain scores were observed. Patients with epidurals had a significantly longer LOS ( p = 0.016). No differences in total opioid use during admission ( p = 0.60) or complications within 30 days ( p = 0.40) were observed. Fifteen studies met inclusion criteria for the systematic review. Fourteen studies included pain scores, with eight noting improved pain control with epidural use. Two studies showed an increased LOS within epidural cohorts. Four studies exhibited higher rates of postoperative complications within epidural cohorts. Opioid use between cohorts was largely equivocal. Epidural analgesia was associated with an increased LOS. A systematic review suggests that perioperative epidurals are associated with increased postoperative complications and LOS. As inpatient hospital capacity is an important consideration among large health care systems where gynecologic oncologists practice, a critical evaluation of interventions that may impact postoperative patient discharge is needed.

  • Open Access

    Trends in pre-fellowship research productivity among matched gynecologic oncology fellows

    by Monica J. Janke, Annie Minns, Michaela M. Pesce, Hannah D. McLaughlin, Shitanshu Uppal, Jean H. Siedel, Christopher X. Hong

  • Open Access

    Improving Serious Illness Communication Skills in Obstetrics and Gynecology Residents: A Pilot Study

    by Monica J. Janke, Laura Taylor, Michael P. Mendez, Anita M. Malone, Andrea McGowan, Yang Liu, Melissa W. Brackmann


  • Open Access

    Patient perspective on virtual prechemotherapy visits in gynecologic oncology

    by Monica J. Janke, Bryan Aaron, Hannah D. McLaughlin, Yang Liu, Shitanshu Uppal

  • Comorbid Vulvar Lichen Sclerosus and High-Grade Squamous Intraepithelial Lesions: A Management Conundrum

    by Monica J. Janke, Jennie DeBlanc, Emily K. Kobernik, Stephanie L. Skala, Guadalupe Lorenzatti Hiles, Rebeca Kelly, Kathryn C. Welch

    Objective: This study aimed to determine if treating lichen sclerosus (LS) with high-potency topical corticosteroids (TCS) increases the risk of high-grade squamous intraepithelial lesion (HSIL) recurrence in patients with comorbid vulvar LS and HSIL. Methods: This is a retrospective study of patients with comorbid vulvar LS and HSIL treated with TCS between 2015 and 2020. Patients with clinically diagnosed or biopsy-proven LS and biopsy-proven HSIL of the vulva were included. Clinical data included demographics, tobacco use, immune-modifying conditions, specimen pathology, treatment types, and HSIL recurrence. Bivariate analysis was performed to compare demographic and clinical characteristics between patients with and without HSIL recurrence. Results: Twenty-six patients with comorbid LS and HSIL were identified. The median age was 66.0 years and median time in treatment for LS was 5.5 years. Thirteen (50%) had recurrence of HSIL and 13 (50%) did not have recurrence. Exposure to high-potency TCS was present in 20 (77%) patients, with 17 (65%) having use of more than 1-year duration and 9 (35%) having use at the time of HSIL diagnosis. When comparing the groups with and without HSIL recurrence, there was no significant difference in high-potency TCS exposure, duration of use, or use at time of HSIL diagnosis. Conclusions: High-potency TCS use for the treatment of LS did not seem to increase the risk of HSIL recurrence in patients with comorbid vulvar LS and HSIL. This suggests that high-potency TCS can be appropriately used for the treatment of LS even when HPV-associated disease is present.


  • The utility of physical examination in ovarian cancer recurrence detection: a retrospective analysis informing virtual surveillance care

    by Monica J Janke, Sarah Santiago, Alli M Straubhar, Shitanshu Uppal

    Objectives Given the recent rapid increase in telemedicine in the setting of the COVID-19 pandemic, we sought to investigate the utility of symptom review, CA125, and physical examination in the detection of ovarian cancer recurrence to determine the role of virtual surveillance care in the COVID-19 era. Methods This retrospective cohort study included patients diagnosed with ovarian cancer between 2013 and 2020 who achieved remission after primary treatment and then had recurrence while in a routine surveillance program. Modalities that detected recurrence including symptoms, CA125, physical examination, or ‘other,’ which was denoted if imaging was obtained for reasons other than suspected recurrence and recurrence was incidentally identified, were recorded. Descriptive statistics were performed to summarize the cohort. Results One hundred and nine patients met inclusion criteria. At time of recurrence, elevated CA125 was present in 97 (89.0%) patients, symptoms in 41 (37.6%), and abnormal physical exam findings in 27 (24.8%). Recurrence was incidentally found with imaging obtained for reasons other than suspicion of recurrence in six (5.5%) patients. Recurrence was suspected based on multiple modalities in 46 (42.2%) patients. Elevated CA125, symptoms, or both were present in 102 (93.6%) patients. Of patients with abnormal physical exam findings, 26 (96.3%) also had elevated CA125 or symptoms present. Recurrence was suspected based on physical exam findings alone in one (0.9%) patient. Conclusions Over 90% of ovarian cancer recurrences were detected by rising CA125, symptoms, or both. Only one patient had recurrence detected by physical examination alone. Given that review of symptoms and CA125 can be conducted virtually, virtual visits may offer a reasonable alternative to in-person visits for ovarian cancer surveillance for patients who have pre-treatment elevated CA125.